Bristol-Myers Squibb Company (BMY) is a biopharmaceutical giant focusing on treatments for cancer, inflammation, and cardiovascular diseases. With a market cap of $95.4 billion, it operates globally. Analysts expect a profit of $1.38 per share in the upcoming Q2 report, showing a 33.3% decrease from the previous year.

For fiscal 2025, BMY is projected to deliver an EPS of $6.56, a significant increase from the previous year. However, fiscal 2026 earnings are expected to drop 8.1% year-over-year to $6.03 per share.

Over the past 52 weeks, BMY stock prices have surged by nearly 15%, outperforming the S&P 500 Index and the Health Care Select Sector SPDR Fund.

Following the release of its Q1 results, BMY stock prices saw a slight increase due to better-than-expected performance. Despite a 5.6% drop in overall topline, the company reported a notable adjusted net income of $3.7 billion and an EPS of $1.80, surpassing consensus estimates.

Bristol-Myers Squibb’s stock holds a consensus “Moderate Buy” rating, with a mean price target of $56.05 suggesting a 19.6% upside potential.

Read more at Yahoo Finance: What to Expect From Bristol-Myers Squibb’s Q2 2025 Earnings Report